Esotropia
18
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
28%
5 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
Botulinum Toxin A vs Strabismus Surgery for Esotropia
Risk Factors And Surgical Outcomes Of Strabismus Reoperation
Vision Therapy Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia
Bifocal Spectacles vs. Single Vision Spectacles for Esotropia Greater at Near
Botulinum Toxin Injection Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia
Accommodation-Related Visual Training Combined with Transcranial Electrical Stimulation Versus Visual Training Alone for the Treatment of Accommodation Dysfunction
Cycloplegic Refraction in Pediatric Patients With Esotropia
Validation of a Smartphone-based Intelligent Diagnosis and Measurement for Strabismus
Changes in Refractive Error in Patients With Both Partially Refractive Esotropia and Amblyopia
Bupivacaine Injection of Eye Muscles to Treat Strabismus
Strabismus Surgery and Driving Ability
Early Versus Delayed Surgery for Infantile Esotropia
Conservative Treatment of Esotropia in Children up to 3 Years Old
Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone
Surgery for Esotropia Under Topical Anesthesia
Congenital Esotropia Observational Study (CEOS)
The Prism Adaptation Study (PAS)
Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin